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Abstract
Background: Although the equitable distribution of diabetic retinopathy (DR) services across Ghana remains
paramount, there is currently a poor understanding of nationwide DR treatment services. This study aims to
conduct a situation analysis of DR treatment services in Ghana and provide evidence on the breadth, coverage,
workload, and gaps in service delivery for DR treatment.
Methods: A cross-sectional study was designed to identify health facilities which treat DR in Ghana from June 2018
to August 2018. Data were obtained from the facilities using a semi-structured questionnaire which included
questions identifying human resources involved in DR treatment, location of health facilities with laser, vitreoretinal
surgery and Anti–vascular endothelial growth factor therapy (Anti-VEGF) for DR treatment, service utilisation and
workload at these facilities, and the average price of DR treatment in these facilities.
Results: Fourteen facilities offer DR treatment in Ghana; four in the public sector, seven in the private sector and
three in the Christian Health Association of Ghana (CHAG) centres. There was a huge disparity in the distribution of
facilities offering DR services, the eye care cadre, workload, and DR treatment service (retinal laser, Anti-VEGF, and
vitreoretinal surgery). The retinal laser treatment price was independent of all variables (facility type, settings,
regions, and National Health Insurance Scheme coverage). However, settings (p = 0.028) and geographical regions
(p = 0.010) were significantly associated with anti-VEGF treatment price per eye.
Conclusion: Our results suggest a disproportionate distribution of DR services in Ghana. Hence, there should be a
strategic development and implementation of an eye care plan to ensure the widespread provision of DR services
to the disadvantaged population as we aim towards a disadvantaged population as we aim towards a universal
health coverage.
Keywords: Cost-utility analysis, Anti-VEGF, Vitreoretinal surgery, Retinal laser, Diabetic retinopathy treatment, Ghana,
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Background
Globally, the number of people living with diabetes is esti-
mated to be 451 million, and this figure is projected to in-
crease to 693 million by the year 2045 if no serious and
committed action is taken [1]. In Sub-Saharan Africa and
other developing countries, diabetes prevalence is known
to have risen more quickly than predicted, from 12.1 mil-
lion in 2010 to 15.5 million in 2017 [2, 3]. Rapid urbanisa-
tion, globalisation and unhealthy lifestyle are widely
acknowledged to have contributed to the growing epi-
demic of diabetes worldwide and in Africa [4]. A case in
point is a developing country such as Ghana experiencing
a rapid increase in diabetes prevalence from 0.2% in 1964,
to 1.9% and 6.46% in 2010 and 2018, respectively [2, 5].
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One of the major complications of diabetes is the de-
velopment of diabetic retinopathy (DR) [6]. Previous
studies have shown that approximately one-third of
people living with diabetes will develop DR and a third
of those with DR will develop vision-threatening diabetic
retinopathy (VTDR) [6]. Moreover, the number of
people with DR is projected to increase from 126.6 mil-
lion in 2010 to 191.0 million by 2030, whilst global esti-
mates show the number with VTDR will increase from
37.3 million to 56.3 million if immediate action is not
taken [7]. DR is the leading cause of vision loss in the
working-age population worldwide [6, 8]. Few studies
have been done on DR in Ghana, and all were centred
on specific health facilities in the country using different
age cut-offs. With the recent increase of diabetes in
Ghana, retinopathies are set to rise, especially with life
expectancy improvement. Therefore, it is imperative to
know what services are in place to treat DR and where
the gaps are to enable the planning of a more systematic
DR screening service nationwide.
Though services for diabetic management have im-
proved in recent years [9], screening and management
for DR are not fully incorporated into the national dia-
betes program [9, 10]. Integrating eye care services into
the general health system helps strengthen the system
for effective planning and service delivery [11, 12].
This study aims to conduct a situation analysis of DR
treatment services in Ghana and provide evidence on
the breadth, coverage, workload, and gaps in service de-
livery for DR treatment. Identifying these gaps will in-
form decisions and policies on where resources should
be allocated. A robust treatment service on offer is es-
sential when considering a more comprehensive
population-based screening in the foreseeable future.
Materials and methods
Study design
The study employed a cross-sectional study design. All
health facilities (e.g., public, private, faith-based or Non-
Governmental Organisation (NGO)-based health facil-
ities) identified to offer treatment services for DR in
Ghana were included in the study. Since this study’s pur-
pose was to conduct a comprehensive situational ana-
lysis countrywide, all health facilities identified to offer
treatment for DR in Ghana were included.
Study setting
Ghana is a lower middle-income country in West Africa
located on the coast of the Gulf of Guinea with Accra as
the capital. With a population of 24,658,823 and a
growth rate of 2.5% according to the 2010 census [13],
Ghana has one of the fastest growing populations in Af-
rica. In 2017, Ghana’s population increased to 28,833,
629 [14]. The country has a GDP per capita of 1513.46
USD and total expenditure on health is 3.6% [15]. Life
expectancy is estimated at 61.7 years and the country
has an under five mortality rate of 78 per 1000 live
births [15]. The average poverty rate in Ghana is far
higher in rural areas compared to urban centres in
Ghana (37.9% for rural and 10.6% for urban). In
addition, the average poverty reduction is far faster in
urban areas than in rural areas (poverty rate is 4 times
higher in rural areas than in urban areas) [16]. The
Upper East and Upper West Regions in Ghana on aver-
age have a third of its population living under the pov-
erty line [16]. Figure 1 is a map of Ghana showing the
distribution of DR services across the ten administrative
regions (please note that the administrative regions were
increased to sixteen after the study was completed).
Eligibility criteria
All hospitals or clinics identified by regional ophthalmol-
ogists to offer some form of treatment for VTDR (laser,
Anti-VEGF, VR surgery) in Ghana were included. Hospi-
tals or clinics could be Government-based, faith-based,
Quasi, private or NGO-based.
Christian Health Association of Ghana (CHAG) is a
form of public private partnership in healthcare delivery.
CHAG is a recognised agency (i.e., faith-based) of the
Ministry of Health made up of a network of 344 health
facilities and health training institutions owned by 33
different Christian Church Denominations. CHAG pro-
vides health care to the most vulnerable and underprivil-
eged population groups in all regions of Ghana,
particularly in the most remote areas.
Quasi facilities are facilities setup or supported by gov-
ernment, but managed privately.
Hospitals or Eye clinics in Ghana that did not offer
any form of treatment for VTDR before 31st December
2017 were excluded from the study.
Participant recruitment
Study participants were ophthalmologists or vitreoretinal
surgeons treating DR in identified facilities. To find such
facilities, a survey questionnaire was sent to all regional
ophthalmologists through an email forwarded by the Na-
tional Eye Care Secretariat to identify study participants
(Fig. 2). Regional ophthalmologists coordinate all regional
eye care activities and have access to the database of re-
gional eye care providers and their contacts. Regional oph-
thalmologists answered questions pertaining to which
hospitals or clinics offer treatment for VTDR within their
region since most treatments are done by ophthalmolo-
gists or Vitreoretinal (VR) surgeons. Hospitals or Clinic
heads were then contacted to identify the person or per-
sons responsible for DR treatment in their facility.
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Data collection
Semi-structured questionnaires were administered by the
Principal Investigator (PI) to study participants to identify
and assess DR treatment services in Ghana. The semi-
structured questionnaire had questions aimed at identifying
human resources involved in DR treatment, location of
health facilities which have retinal laser, VR surgery and
Anti-VEGF for DR treatment, service utilisation and work-
load at these facilities, and the average price of DR treatment
in these facilities. DR registers and records were examined
to identify the number of retinal lasers, Anti-VEGF and VR
surgeries performed in 2017. A checklist was also used to
identify equipment used in DR treatment. Data collection
covered a period from 11th June 2018 to 13th August 2018.
Quality control
Three Ophthalmologists in Africa, working in facilities
with retinal laser took part in their work facilities in Af-
rica took part in the pretesting of questionnaires. The
questionnaires were edited as a result of the feedback re-
ceived from the pretest. Questionnaires were written in
English, which is the official language of Ghana. The
principal investigator administered questionnaires and
checklists personally. Data entered was double-checked
to minimise errors.
Ethical approval
Ethical approval was obtained from the institutional re-
view committees at the London School of Hygiene and
Fig. 1 Location and type of facility delivering treatment for Diabetic Retinopathy in Ghana
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Tropical Medicine (Reference Number: 15308) and the
institutional review boards of three major hospitals in
Ghana; namely Korle Bu Teaching Hospital (Reference
Number: KBTH-IRB/00060/2018), Komfo Anokye
Teaching Hospital (Reference Number: CHRPE/AP/328/
18) and 37 Military Hospital (Reference Number:
37MH-IRB IPN/218/2018). Informed consent and per-
mission were obtained from facility heads and study par-
ticipants before interviews took place. Participant names
were not included in questionnaires and facility names
were excluded in reports. Facility names were replaced
with codes to ensure confidentiality.
Data analysis
Data analysis was performed using Statistical Product
and Service Solution (IBM Corporation IBM® SPSS® Sta-
tistics for Windows, Version 25.0 Armonk, NY) compat-
ible with Windows 10. Multiple data cleaning was
performed as part of data quality checks. The analytic
sample comprised the health facilities treating DR. De-
scriptive statistics were used to assess the frequencies
and proportions of demographic variables (facility type,
settings, regions, and other DR service parameters). The
association between demographic variables and the price
of DR treatments were investigated using a one-way ana-
lysis of variance (ANOVA). Statistical significance was
set at p < 0.05.
Results
Fourteen eye care facilities were identified to fulfil the
inclusion criteria and all of them agreed to participate in
the study (see Fig. 1 and Table 1). All facilities partici-
pated in the study (100% response rate). Seven facilities
were private, four were public and three were faith-
based, part of the CHAG.
Diabetic retinopathy treatment facilities
Table 2 presents the demographic profile of the fourteen
facilities offering DR treatment services in Ghana.
The majority were private facilities (50.0%) and were lo-
cated in urban settings (78.6%). Most of the facilities
were concentrated in the Greater Accra (50.0%) and
Ashanti (21.4%) and with a fewer in the Brong Ahafo
(7.1%) and Volta Regions (7.1%).
Most of the facilities treated DR based on the clinical
expertise defined as the proficiency and judgement made
by individual clinicians acquired through experience and
practice intended to optimize or improve patient care
(66.7%). A greater proportion of the facilities (64.3%) re-
ported using a reciprocal referral pathway; thus, physi-
cians at the same or higher level of health care system
refer to each other and vice versa with the aim of getting
feedback from referral facilities. With respect to DR
treatments, the following were recorded for the proce-
dures: Anti-VEGF (42.9%); retinal laser photocoagulation
(35.7%) and vitreoretinal surgery (21.4%). The majority
(51.9%) of the facilities indicated that an ophthalmologist
treated DR, and most (33.3%) received continuing med-
ical education through workshops. A preponderance
(78.6%) of the facilities had DR treatment records; how-
ever, many (78.6%) had no NHIS coverage (Table 2).
Human resource treating diabetic retinopathy in Ghana
Non-surgical DR treatment in Ghana is delivered by 19
General Ophthalmologists, 11 vitreoretinal surgeons,
eight ophthalmic nurses and one optometrist. The distri-
bution of these eye care professionals across setting,
Fig. 2 Identification of study participants
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facility types and regions in Ghana is shown in Table 3.
All 11 vitreoretinal surgeons (100%) and one optometrist
were only practising in private urban facilities. The ma-
jority of ophthalmologists and ophthalmic nurses were
practising in an urban setting (78.9% versus 62.5%,
respectively).
In terms of distribution across the regions of Ghana,
eye care professionals were found in only five regions of
Ghana; namely Greater-Accra, Ashanti, Northern and
Brong Ahafo, Volta), with ophthalmologists having a
representation in all four regions.
The distribution of the total workload across setting,
facility types and regions in Ghana is shown in Table 3.
Workload is defined as the total number of eyes treated
for DR using retinal lasers, Anti-VEGF, or VR surgery.
The total number of people treated is the total number
of persons who visited the health facilities for DR treat-
ment (the number of treatments received by a person is
counted as one).
Equipment for diabetic retinopathy treatment in Ghana
There are variations in the geographical location and dis-
tribution of equipment used in DR treatment (Table 3). A
total of nine retinal cameras, ten retinal laser machines
and seven OCT machines were enumerated in the study.
Interestingly, most of the retinal lasers (70%) are concen-
trated in the Greater Accra region, with only one retinal
laser located in the Ashanti, Brong Ahafo and Volta Re-
gions of Ghana. Similarly, most retinal cameras are con-
centrated in the Greater Accra region (55.6%). All OCT
machines were found in urban settings (100%). Thus,
there is a gap in equipment availability, especially in the
extreme north and south-western part of Ghana.
Utilisation of diabetic retinopathy treatment Services in
Ghana
The level of utilization of DR treatment Services utilisa-
tion (in terms of the number of eyes treated) in Ghana is
also shown in Table 3. The majority of retinal lasers to
treat DR were performed in private facilities (82.3%) and
urban settings (98.7%). Similarly, Anti-VEGF treatment
for DR was done in the private sector facilities (86.6%)
and urban settings (99.4%). Of note, all vitreoretinal sur-
geries were performed in urban settings and the Greater
Accra region.
Price of diabetic retinopathy treatment in Ghana
The price of recommended DR treatments (anti-VEGF
injection and retinal laser photocoagulation) varied
across different settings, facility types and regions in
Ghana (Table 4). No factor was significantly associated
(p > 0.05, for all) with price per retinal laser treatment in
our analyses. However, geographical settings (F-statistic
F (1,12) = 6.22, p = 0.028) and Regions (F-statistic F (4,
9) = 6.38, p = 0.010) significantly influenced price per eye
of Anti-VEGF treatments. Post Hoc test for the Regions
Variable was not statistically feasible because two sub-
groups had fewer than two cases. The price per eye of
Anti-VEGF treatment on average was significantly
higher in the urban settings (500GHS) compared to the
rural setting (133.3GHS). The average price in the
Greater Accra region was more than two times higher
compared to that in the Ashanti region of Ghana.
National assessment of diabetic retinopathy treatment
services
The Ghana National Eye Care Unit completed a struc-
tured questionnaire aimed at understanding DR
Table 1 List of Eligible Eye Care Facilities
N Facility Name Region Type of facility
1 Korle Bu Teaching Hospital Greater Accra Public
2 Komfo Anokye Teaching Hospital Ashanti Public
3 37 Military Hospital Greater Accra Public
4 Margret Marquart Catholic Hospital Volta CHAG
5 St. Mary’s Hospital Brong-Ahafo CHAG
6 St. Thomas Eye Hospital Greater Accra Private
7 Dr. Agarwal’s Eye Hospital Greater Accra Private
8 Tamale Teaching Hospital Northern Public
9 Friends Eye Centre Northern Private
10 Sight for Africa Greater Accra CHAG
11 Dziram Eye Clinic Greater Accra Private
12 Interstar Eye Clinic and Laser Centre Greater Accra Private
13 Madonna Health Services Ashanti Private
14 Sunshine Ophthalmic Consult Ashanti Private
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Regions with diabetic retinopathy treatment services
Greater Accra Region 7 50.0
Ashanti Region 3 21.4
Northern Region 2 14.3
Brong Ahafo Region 1 7.1
Volta Region 1 7.1
Guidelines for diabetic retinopathy
ICO guidelines 6 33.3





One way 5 35.7
Reciprocal 9 64.3
Diabetic retinopathy treatments
Retinal Laser 10 35.7
Anti-VEGF 12 42.9
Vitreoretinal surgery 6 21.4
Health professionals treating diabetic retinopathy
Vitreoretinal surgeon 11 28.2
Ophthalmologists 19 48.7
Optometrists 1 2.6
Ophthalmic nurses 8 20.5
Continuing medical education
Formal training by a regulated body 7 25.9
Regular informal updates 5 18.5
Workshops 9 33.3
Updates on guidelines 6 22.2
Records on diabetic retinopathy treatments
No 3 21.4
Yes 11 78.6
Indicators that are monitored
Type of treatment 11 26.8
Eye treated 11 26.8
Number of times eye treated 9 22.0
Visual acuity after treatment 10 24.4
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treatment at the national level. From the completed
questionnaire, Ghana has a national health plan (which
needs an update) and a national diabetes health plan
covering primary prevention of blindness; community
awareness and patient education; clinical care, services
and supplies; and some complications but not including
visual impairment. Ghana has a national prevention of
blindness plan which lists DR as a priority.
From 11th June to 14th June 2018, stakeholders met
to draw guidelines for DR management at the various
levels of the existing health system. These guidelines
cover primary prevention, secondary prevention and ter-
tiary prevention of visual impairment from DR. They
also cover the treatment of DR, referral and periodic
follow-ups. Guidelines for DR management are in the
final stages of completion. National protocols for DR
screening and treatment are currently in preparation
and almost ready.
Ghana has a nationwide information management sys-
tem, the District Health Information Management
System (DHIMS) which now captures DR treatment ser-
vices as of April 2018. It captures information on the
number of retinal lasers done, and the number of
vitreoretinal surgeries done.
Some DR treatment services covered by the National
Health Insurance Scheme are diabetes care and DR
screening. Optometrists can play the following roles in
DR treatment services: Health Education; Awareness
Creation; DR screening; DR Grading; DR Counselling.
Discussion
This novel study presents the situation analysis of DR
treatment services in Ghana and provides evidence on
the breadth, coverage, workload and gaps in service de-
livery for DR treatment in Ghana. The results show geo-
graphical variation in the distribution of DR services,
equipment, and human resource across Ghana. Further-
more, the price of DR treatment (anti-VEGF) was
significantly influenced by the setting and regions in
which patients are utilising these services.
The estimated burden of diabetes mellitus is 3.6% of
the general population aged 20 years and above and for
Ghana, which translates to 533,000 Ghanaians living
with diabetes mellitus [18]. Of this number, an estimated
34% of them constituting about 181, 220 diabetics have
DR [19] while about 53,300 about persons with diabetes
representing 10% will have VTDR [19]. Considering that
only 14 facilities offer DR treatment services at the end
of December 2017, serving 53,330 people needing treat-
ment for VTDR, will put a considerable burden on re-
sources available in the various health facilities. Besides
these numbers, the majority of the facilities are in Accra,
the nation’s capital leaving other regions deprived of DR
treatment services.
In Ghana, retinal lasers and intravitreal Anti-VEGF in-
jections are given by Ophthalmologists and vitreoretinal
surgeons, which is recommended by the ICO [20]
although in other places like the United Kingdom, oph-
thalmic nurses are allowed to give Anti-VEGF injections
[21, 22]. Our study indicates that VR surgeons and Oph-
thalmologists involved in DR treatment are not equally
distributed around the country leaving gaps in DR treat-
ment services between regions, urban and rural areas,
which are consistent with findings from a similar study
in the western province of Sri-Lanka in 2017 [8]. Of the
11 facilities with VR surgeons, 90.9% are located in the
Greater Accra region and the remaining 9.1% in the
Ashanti region leaving the rest of the country deprived
of vitreoretinal services. DR patients in the northern part
of the country will have challenges travelling down to
health facilities in these regions located in the southern
part of the country especially if they are from areas
where resources are limited and road networks are bad.
Reasons why VR surgeons are concentrated in these re-
gions may be because these are the two most populous
regions in the country. Together, these regions represent
34.87% of Ghana’s total population [23, 24].





NHIS services on diabetic retinopathy
Diabetes care 3 33.3
DR screening 3 33.3
Laser photocoagulation 1 11.1
Anti-VEGF 1 11.1
Vitreoretinal surgery 1 11.1
n frequency of facilities, % percentage frequency of facilities, CHAG Christian Health Association of Ghana, Anti-VEGF Anti-vascular endothelial growth factor
therapy, NHIS National Health Insurance Scheme
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Table 3 Distribution of personnel, workload, and diabetic retinopathy treatment services in Ghana
Variable Setting Facility type Regions
Rural Urban Public CHAG Private GAR AR NR BAR VR
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Health professionals treating DR
Vitreoretinal surgeon 0 (0.0) 11 (100.0) 4 (36.36) 1 (9.09) 6 (54.55) 10 (90.9) 1 (9.1) 0 (0.0) 0 (0.0) 0 (0.0)
Ophthalmologist 4 (21.1) 15 (78.9) 6 (31.6) 3 (15.8) 10 (52.6) 10 (52.63) 4 (21.05) 3 (15.79) 1 (5.26) 1 (5.26)
Optometrist 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 1 (100) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ophthalmic nurse 3 (37.5) 5 (62.5) 0 (0.0) 3 (37.5) 5 (62.5) 5 (62.5) 0 (0.0) 0 (0.0) 0 (0.0) 3 (37.5)
DRT
Retinal laser photocoagulation 3 (30.0) 7 (70.0) 2 (20.0) 3 (30.0) 5 (50.0) 6 (60.0) 1 (10.0) 1 (10.0) 1 (10.0) 1 (10.0)
Anti-VEGF 1 (9.1) 11 (90.9) 4 (33.33) 1 (8.33) 7 (58.33) 7 (58.3) 3 (25.0) 2 (16.7) 0 (0.0) 0 (0.0)
Vitreoretinal surgery 0 (0.0) 6 (100.0) 2 (33.3) 0 (0.0) 4 (66.7) 5 (83.3) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0)
Guidelines for DRT 3 (33.3)
ICO guidelines 1 (16.7) 5 (83.3) 2 (33.3) 1 (16.7) 3 (50.0) 2 (33.3) 2 (33.3) 1 (16.7) 1 (16.7) 0 (0.0)
Clinical expertise 3 (25.0) 9 (75.0) 4 (33.3) 3 (25.0) 5 (41.7) 5 (41.7) 3 (25.0) 2 (16.7) 1 (8.3) 1 (8.3)
Routine diabetic examination 2 (28.6) 5 (71.4) 3 (42.86) 2 (28.57) 2 (28.57) 4 (57.14) 0 (0.0) 1 (14.29) 1 (14.29) 1 (14.3)
Referral pathway
One-way 0 (0.0) 5 (100.0) 1 (20.0) 1 (20.0) 3 (60.0) 4 (80.0) 1 (20.00) 0 (0.0) 0 (0.0) 0 (0.0)
Reciprocal 3 (33.3) 6 (66.7) 3 (33.33) 2 (22.22) 4 (44.44) 3 (33.33) 2 (22.22) 2 (22.22) 1 (11.11) 1 (11.1)
Records availability 3 (27.3) 8 (72.7) 2 (18.18) 3 (27.27) 6 (54.55) 5 (45.45) 2 (18.18) 2 (18.18) 1 (9.09) 1 (9.09)
Number of people treated
Retinal laser 33 (1.9) 1669 (98.1) 293 (17.22) 117 (6.87) 1292 (75.91) 1461 (85.84) 208 (12.22) 5 (0.29) 10 (0.59) 18 (1.1)
Anti-VEGF 15 (0.8) 1953 (99.2) 268 (13.62) 124 (6.30) 1576 (80.08) 1716 (87.20) 229 (11.64) 23 (1.17) 0 (0.0) 0 (0.0)
Vitreoretinal surgery 0 (0.0) 407 (100.0) 22 (5.41) 21 (5.16) 364 (89.43) 407 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Number of eyes treated
Retinal laser photocoagulation 37 (1.3) 2910 (98.7) 406 (13.78) 117 (3.97) 2424 (82.25) 2589 (87.85) 321 (10.89) 9 (0.31) 10 (0.34) 18 (0.6)
Anti-VEGF 21 (0.6) 3435 (99.4) 338 (9.78) 124 (3.59) 2994 (86.63) 3103 (89.79) 318 (9.20) 35 (1.01) 0 (0.0) 0 (0.0)
Vitreoretinal surgery 0 (0.0) 533 (100.0) 22 (4.13) 21 (3.94) 490 (91.93) 533 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Checklist for DRT services
Screening protocols for DM 2 (28.6) 5 (71.4) 4 (57.14) 1 (14.29) 2 (28.57) 3 (42.86) 1 (14.29) 2 (28.57) 1 (14.29) 0 (0.00
Screening protocols for DR 1 (11.1) 8 (88.9) 4 (44.44) 1 (11.11) 4 (44.44) 6 (66.67) 1 (11.11) 2 (22.22) 0 (0.0) 0 (0.0)
Grading protocols for DR 1 (11.1) 8 (88.9) 4 (44.44) 1 (11.11) 4 (44.44) 6 (66.67) 1 (11.11) 2 (22.22) 0 (0.0) 0 (0.0)
Treatment protocols for DR 1 (11.1) 8 (88.9) 4 (44.44) 1 (11.11) 4 (44.44) 6 (66.67) 1 (11.11) 2 (22.22) 0 (0.0) 0 (0.0)
DR treatment registry/records 2 (18.2) 9 (81.8) 3 (27.27) 2 (18.18) 6 (54.55) 7 (63.64) 1 (9.09) 2 (18.18) 1 (9.09) 0 (0.0)
Anti-VEGF drugs 1 (8.3) 11 (91.7) 4 (33.33) 1 (8.33) 7 (58.33) 7 (58.33) 3 (25.00) 2 (16.67) 0 (0.0) 0 (0.0)
27 needle and 1ml syringe 2 (15.4) 11 (84.6) 4 (30.77) 2 (15.38) 7 (53.85) 7 (53.85) 3 (23.08) 2 (15.38) 0 (0.0) 1 (7.69)
Operating microscope 3 (21.4) 11 (78.6) 4 (28.57) 3 (21.43) 7 (50.00) 7 (50.00) 3 (21.43) 2 (14.29) 1 (7.14) 1 (7.14)
Retinal Laser machine 2 (20.0) 8 (80.0) 3 (30.00) 3 (30.00) 4 (40.00) 7 (70.00) 1 (10.0) 0 (0.0) 1 (10.00) 1 (10.0)
Vitrectomy machine 1 (12.5) 7 (87.5) 2 (25.00) 2 (25.00) 4 (50.00) 6 (75.00) 1 (12.5) 0 (0.0) 0 (0.0) 1 (12.5)
Fundus/retinal camera 2 (22.2) 7 (77.8) 2 (22.22) 2 (22.22) 5 (55.56) 5 (55.56) 2 (22.22) 1 (11.11) 1 (11.11) 0 (0.0)
OCT machine 0 (0.0) 7 (100.0) 3 (42.86) 1 (14.29) 3 (42.86) 6 (85.7) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0)
Pan retinal photocoagulation lens 1 (10.0) 9 (90.0) 3 (30.0) 2 (20.0) 5 (50.0) 7 (70.00) 2 (20.00) 0 (0.0) 0 (0.0) 1 (10.0)
FFA/ICG angiography 1 (16.7) 5 (83.3) 2 (33.3) 1 (16.7) 3 (50.0) 4 (66.67) 1 (16.67) 0 (0.0) 0 (0.0) 1 (16.7)
Slit lamp biomicroscope 3 (21.4) 11 (78.6) 4 (28.6) 3 (21.4) 7 (50.0) 7 (50.0) 3 (21.43) 2 (14.29) 1 (7.14) 1 (7.14)
Direct ophthalmoscope 3 (21.4) 11 (78.6) 4 (28.6) 3 (21.4) 7 (50.0) 7 (50.00) 3 (21.43) 2 (14.29) 1 (7.14) 1 (7.14)
Indirect ophthalmoscope 3 (21.4) 11 (78.6) 4 (28.6) 3 (21.4) 7 (50.0) 7 (50.00) 3 (21.43) 2 (14.29) 1 (7.14) 1 (7.14)
90 D lens 3 (23.08) 10 (76.92) 4 (30.77) 3 (23.08) 6 (46.15) 7 (53.85) 2 (15.38) 2 (15.38) 1 (7.69) 1 (7.69)
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Moreover, we found disparities in the distribution of the
number of ophthalmologists that administer DR treatment
services across the country. Our results are consistent with
similar studies that reported huge service delivery gaps in
developing countries [8, 25–27]. The World Health
Organization (WHO) recommendation for human resource
distribution for low-income countries, highlights that a
minimum of four Ophthalmologists should serve a million
population [26]. In Ghana, there are 91 ophthalmologists
serving a population of approximately 30 million [28]. This
number is less than what is needed. Furthermore some
Ophthalmologists are not specialized in delivery of care for
DR. Evidence from the current eye health systems assess-
ment report [29] for Ghana showed an inequitable distribu-
tion of ophthalmologist across the country with many
regions being understaffed. In addition, the report showed
a limited number of sub-specialty (including experts in DR
treatment) with the exception of paediatric ophthalmology
[29]. Furthermore, a study analysing eye health delivery in
Ghana by Morny and colleagues showed a positive skew-
ness in the distribution of human resources across two re-
gions (Ashanti and Greater Accra regions) and with limited
specialist eye care (such as DR services) equipment across
the nation [28]. Our findings show an under-utilisation of
human resources, especially with regions like the Eastern,
Central, Western, Upper East and Upper West having no
access to any form of DR treatment services.
In terms of DR treatment facilities’ geographical loca-
tion, most were concentrated in one region (Greater
Accra Region), leaving the other regions underserved.
Out of the total of ten administrative regions, five had
no facilities providing DR services. Thus, the majority of
patients have no access to services within their reach.
The lack of available services also means that DR and
VTDR may only get noticed at advanced stages and even
then, they will have to travel at greater cost to reach these
referral centres where these services are provided. This has
cost implications, and patients who cannot afford the cost
of travelling to seek these services will have to be left to
their fate. This goes against the fundamental principle of
universal health coverage which aims to provide financial
risk protection for persons seeking health care.
We observed that the price of Anti-VEGF per eye for DR
treatment differs significantly across the facility’s geograph-
ical location and regions. Our findings contrast with results
from other similar studies which showed an association be-
tween the price of treatment and uptake of DR services
[30–32]. For example, in a qualitative hospital-based survey
in Nigeria, Ibrahim et al. [30] reported cost of DR treat-
ment, including Anti-VEGF, was a disenabling factor for
assessing DR treatment services. In addition, a study by
Fletcher et al. [32] in rural India identified direct and/or in-
direct cost as a barrier to the lower uptake of DR services.
Furthermore, in a randomised control trial among people
with diabetes mellitus, Lian et al. [31] demonstrated that
those with co-payment of service had lower DR screening
uptake compared with subjects that received care with no
charges. Our study shows that despite the higher cost of
treatment, private centres located in the main cities deliv-
ered the majority of DR treatment in the country. This dif-
fers from the inverse care law [33], which states that “the
availability of good medical care tends to vary inversely with
the need for the population served”. There is some evidence
that shows that diabetes prevalence in Ghana is higher in
urban centres as compared to rural areas [5, 34, 35]. This
creates a higher demand in the cities, where the population
are also likely to have a higher purchasing power, generat-
ing more demand for DR treatment services.
On the other hand, our results indicate that uptake of
treatment services was not dependent on the price of
treatment but may have been influenced by other factors
like setting (facility location) [36]. This study observed that
facilities with higher prices for laser treatment did more
lasers than those with the lowest prices. The difference
observed was that a large proportion (99%) of the lasers
were done in urban centres rather than in rural settings.
The purchasing power of residents of urban areas is
higher than those in rural areas, which may have influ-
enced DR treatment services’ uptake within these settings.
Despite the study presenting preliminary nationwide
data on DR treatment services, it still has some limita-
tions. Our findings may have been underestimated since,
in some facilities, the ophthalmologists admitted that
not all completed treatments were imputed in the
Table 3 Distribution of personnel, workload, and diabetic retinopathy treatment services in Ghana (Continued)
Variable Setting Facility type Regions
Rural Urban Public CHAG Private GAR AR NR BAR VR
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
78 D lens 2 (15.4) 11 (84.6) 4 (30.77) 2 (15.38) 7 (53.85) 7 (53.85) 3 (23.08) 2 (15.38) 1 (7.69) 0 (0.0)
20 D lens 3 (21.4) 11 (78.6) 4 (28.57) 3 (21.43) 7 (50.0) 7 (50.0) 3 (21.43) 2 (14.29) 1 (7.14) 1 (7.14)
Three-mirror contact lens 2 (16.7) 10 (83.3) 4 (33.3) 2 (16.7) 6 (50.0) 7 (58.33) 2 (16.67) 2 (16.67) 0 (0.0) 1 (8.33)
Visual acuity chart 3 (21.4) 11 (78.6) 4 (28.6) 3 (21.4) 7 (50.0) 7 (50.0) 3 (21.43) 2 (14.29) 1 (7.14) 1 (7.14)
n frequency, % percentage frequency, CHAG Christian Health Association of Ghana, GAR Greater Accra Region, AR Ashanti Region, NR Northern Region, BAR Brong
Ahafo Region, VR Volta Region, DRT Diabetic Retinopathy Treatments, Anti-VEGF Anti-vascular endothelial growth factor therapy, DM Diabetes mellitus, DR Diabetic
retinopathy, OCT Optical Coherence Tomography, FFA Fluorescein Angiography, ICG Indocyanine Green, D Dioptres; Workload is defined as the total number of
eyes treated for DR using retinal lasers, Anti-VEGF or by VR surgery
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records folder and that they did more lasers and anti-
VEGF treatments than were recorded. This could lead to
underestimating people treated for DR. Facilities, which
started DR treatment in 2018 and a private facility that
was temporarily closed down at the time of the study
were excluded.
Conclusions
It is imperative to put measures in place to deal with DR
given the disparities in the distribution of human
resources and facilities for managing DR in Ghana. This
study will aid in planning services for DR, ensuring re-
sources are fairly distributed and access to treatment
services are readily available countrywide. Services for
DR should be incorporated into mainstream diabetes
care so that treatment services will be readily accessible
to people living with VTDR. DR treatment services
should be included in NHIS packages allocated for dia-
betes complications to ease the financial burden of
people with VTDR.
Table 4 Comparison of Cost of Diabetic Retinopathy Treatment to Annual Average Incomes in Ghana
Price per eye Retinal laser GH¢) Mean laser price as % of Mean laser price as % of
n Mean Std.
Deviation
Minimum Maximum p -
value
Mean household income (GH¢) mean annual per capita income (GH¢)
Facility type
Public 4 262.50 205.65 0.00 450.00 0.499
CHAG 3 200.00 100.00 100.00 300.00
Private 7 428.57 380.63 0.00 1000.00
Setting
Rural 3 183.33 76.38 100.00 250.00 0.349
Urban 11 372.73 325.09 0.00 1000.00
Regions
GAR 7 528.57 279.67 200.00 1000.00 0.175 0.82 2.45
AR 3 133.33 230.94 0.00 400.00 0.18 0.24
NR 2 125.00 176.78 0.00 250.00 0.55 2.17
BAR 1 200.00 . 200.00 200.00 0.65 1.59
VR 1 100.00 . 100.00 100.00 0.32 1.35
NHIS Coverage
No 11 331.82 327.32 0.00 1000.00 0.994
Yes 3 333.33 202.07 100.00 450.00
Price per eye Anti-VEGF GH¢) Mean anti-VEGF price as % of
mean household income (GH¢)
Mean anti-VEGF price as % of mean
annual per capita income (GH¢)
Facility type
Public 4 487.50 232.29 250.00 800.00 0.181
CHAG 3 166.67 288.68 0.00 500.00
Private 7 492.86 242.26 200.00 950.00
Setting
Rural 3 133.33 230.94 0.00 400.00 0.028
Urban 11 500.00 224.72 200.00 950.00
Regions
GAR 7 607.14 196.70 400.00 950.00 0.010 0.94 2.81
AR 3 250.00 50.00 200.00 300.00 0.34 0.44
NR 2 450.00 70.71 400.00 500.00 1.96 7.83
BAR 1 0.00 . 0.00 0.00 0.00 0.00
VR 1 0.00 . 0.00 0.00 0.00 0.00
NHIS Coverage
No 11 413.64 216.90 0.00 800.00 0.181
Yes 3 450.00 476.97 0.00 950.00
n number of facilities, Anti-VEGF Anti-vascular endothelial growth factor therapy, CHAG Christian Health Association of Ghana, NHIS National Health Insurance
Scheme, GAR Greater Accra Region, AR Ashanti Region, NR Northern Region, BAR Brong Ahafo Region, VR Volta Region, Std. Deviation standard deviation; Statistical
test employed one-way Analysis of variance (ANOVA) and significance set at p < 0.05. Mean annual household income (GH¢) and Mean annual per capita income
(GH¢) is based on the Ghana Living Standards Survey Round 7 (GLSS-7) Report. Report [17]
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